New data suggest Risperdal (risperidone) can produce symptom relief when used alone to treat bipolar mania.

17 декабря, 2002
12/10/2002 In a new study, individuals with bipolar disorder experienced significant relief of manic symptoms when treated with Risperdal . The research was presented for the first time at a major US psychiatry meeting. Chemical Business NewsBase - Press Release via NewsEdge Corporation : 12/10/2002 In a new study, individuals with bipolar disorder (also known as manic depression) experienced significant relief of manic symptoms when treated with Risperdal (risperidone). The research was presented for the first time at a major US psychiatry meeting. The multi-centre, double-blind, study involved 259 patients with "bipolar 1" disorder. These individuals were randomly assigned to receive either 1-6 mg of Risperdal daily (average dose was 4.1 mg) or placebo for three weeks. Patients' symptoms were assessed at the beginning of the research using the YMRS (Young Mania Rating Scale, a widely accepted measurement of manic symptoms), and the primary measure of efficacy was the average change in the YMRS score by the end of the study. Patients taking Risperdal in the study experienced improvements in their YMRS scores that were significantly greater than those for individuals who received placebo. Significant improvements were observed with Risperdal as early as day three and were sustained throughout the trial. In addition, significant symptom relief was shown using another assessment tool, the Clinicians' Global Impression-Severity scale. Physicians using this device reported that individuals receiving Risperdal improved twice as much as patients who took placebo. More Risperdal-treated patients completed the study than those who took placebo. Janssen Pharmaceutica Products LP, a wholly owned subsidiary of Johnson & Johnson, has a long track record in developing and marketing treatments for central nervous system disorders. Based in Titusville, NJ, Janssen Pharmaceutica Products' other speciality areas include pain management, treatment of fungal infections and therapy for gastrointestinal conditions. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire http://www.jnj.com <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>
Разделы
Новости